

# [FoundationOne CDx gets expanded approval](#)

written by CAP TODAY

February 19, 2020

February 2020—Foundation Medicine has received FDA approval for its FoundationOne CDx to be used as a companion diagnostic for Piqray (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, human epidermal growth factor receptor 2-negative, *PIK3CA*-mutated advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

[Foundation Medicine](#), 888-988-3639



©2026 CAP TODAY, all rights reserved.